Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Two-arm, Double-blind, Multi-center, Randomized Study of the Combination of Oral WX-671 Plus Capecitabine vs. Capecitabine Monotherapy in First-line Her2-negative Metastatic Breast Cancer

NCT00615940 is registered in ClinicalTrials.gov with Heidelberg Pharma AG as lead sponsor.

NCT NCT00615940
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00615940 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Two-arm, Double-blind, Multi-center, Randomized Study of the Combination of Oral WX-671 Plus Capecitabine vs. Capecitabine Monotherapy in First-line Her2-negative Metastatic Breast Cancer
Lead sponsor
Heidelberg Pharma AG
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2008
Completion date
April 30, 2012
Enrollment
132 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer